DPH6 Antibody

What is DPH6 and what role does it play in diphthamide biosynthesis?

DPH6 (also known as ATPBD4 or ATP-binding domain-containing protein 4) functions as an amidase that catalyzes the final step in diphthamide biosynthesis. Specifically, DPH6 completes the conversion of diphthine to diphthamide through an amidation reaction that requires ATP and ammonia. This process modifies a specific histidine residue on eukaryotic translation elongation factor 2 (eEF2), creating the fully functional diphthamide modification . Studies with yeast have demonstrated that DPH6 contains an essential adenine nucleotide hydrolase domain that facilitates this reaction, and knockout models show accumulation of diphthine-modified eEF2, confirming DPH6's role in the amidation step .

How does diphthamide biosynthesis impact cellular function and translation?

Diphthamide modification of eEF2 influences several aspects of cellular function and translation. Complete diphthamide synthesis is required for:

• Optimal translational accuracy and fidelity

• Normal cell growth patterns

• Prevention of increased ribosomal -1 frameshifting

• Proper response to translation inhibitors

Additionally, diphthamide-modified eEF2 serves as the target for bacterial toxins including diphtheria toxin (DT) and Pseudomonas exotoxin A (PE), which irreversibly ADP-ribosylate this modification, halting protein synthesis . Research with MCF7 breast cancer cell lines demonstrates that loss of diphthamide modification not only confers resistance to these toxins but also influences signaling pathways, particularly pre-activating NF-κB and TNF receptor pathways, which can hypersensitize cells to TNF-mediated apoptosis .

What commercially available DPH6 antibodies exist and what are their validated applications?

Current commercially available options include a biotin-conjugated polyclonal DPH6 antibody raised in rabbit that targets human DPH6. This antibody has been validated for ELISA applications and is classified for research use only . When selecting a DPH6 antibody, researchers should verify:

This antibody targets the protein responsible for catalyzing the amidation reaction that converts diphthine to diphthamide using ammonium and ATP .

How should experiments be designed to study DPH6 function in diphthamide biosynthesis?

When designing experiments to study DPH6 function, researchers should consider a multi-faceted approach:

• Genetic manipulation strategies: Generate DPH6 knockout or knockdown cell lines using CRISPR-Cas9 or RNAi approaches. Based on studies with yeast and mammalian cells, complete inactivation of DPH6 produces viable cells without proper diphthamide modification, allowing for functional analysis .

• Protein-protein interaction assays: As DPH6 binds to eEF2, co-immunoprecipitation (co-IP) assays should be designed to examine this interaction and potential regulatory dynamics. Previous studies have used HA-tagged Dph6 and (His)6-marked eEF2 to examine their interactions .

• Enzymatic activity assessment: Design ATP hydrolysis assays to measure DPH6 amidase activity, as the protein contains an essential adenine nucleotide hydrolase domain required for function .

• Mass spectrometry analysis: Include mass spectrometry to detect diphthine accumulation in DPH6-deficient cells, which would confirm a block in the final amidation step .

• Toxin sensitivity tests: Assess sensitivity to diphtheria toxin and other ADP-ribosylating toxins, as cells lacking functional diphthamide modification show resistance to these toxins .

Incorporating appropriate controls, including wild-type cells and other DPH gene mutants (DPH1-5, DPH7), allows for comparative analysis across the diphthamide synthesis pathway .

What parameters should be considered when using Design of Experiments (DOE) for DPH6 antibody-related research?

When applying DOE principles to DPH6 antibody research, consider:

• Statistical design selection: For early-phase research, factorial designs (full or fractional) are most appropriate. These designs allow for systematic exploration of multiple parameters with minimal resource expenditure .

• Critical process parameters: Identify key variables that might affect antibody performance or experimental outcomes, such as:

  • pH conditions for antibody binding

  • Antibody concentration

  • Incubation time and temperature

  • Buffer composition

  • Sample preparation methods

• Response variables: Define clear measurable outcomes that indicate successful experimentation, such as:

  • Signal-to-noise ratio in immunoblotting

  • Specificity in immunoprecipitation

  • Reproducibility across replicates

  • Sensitivity thresholds

• Scale-down model selection: Choose appropriate small-scale systems that mimic larger experimental conditions to avoid introducing variability during execution .

• Design space definition: Establish the "sweet spot" or design space where all quality attributes meet specifications, which helps in robust setpoint calculations for optimal experimental conditions .

Implementation should include center-points for robustness assessment and clear specification limits that define successful outcomes .

How can DPH6 antibodies be utilized to investigate the relationship between diphthamide modification and cellular signaling pathways?

DPH6 antibodies can serve as powerful tools for exploring the unexpected link between diphthamide modification and cellular signaling:

• Co-immunoprecipitation studies: Use DPH6 antibodies to pull down protein complexes and identify potential interactors beyond eEF2 that might connect diphthamide synthesis to signaling pathways. Studies have revealed that diphthamide deficiency pre-activates NF-κB and death receptor pathways .

• Chromatin immunoprecipitation (ChIP) assays: Investigate whether DPH6 or associated proteins interact with chromatin and influence gene expression, particularly genes involved in TNF receptor signaling and apoptosis regulation.

• Proximity labeling experiments: Combine DPH6 antibodies with proximity labeling techniques (BioID, APEX) to map the protein neighborhood around DPH6 in different cellular compartments and under various stress conditions.

• Phosphorylation state analysis: Examine whether DPH6 is regulated by phosphorylation in response to cellular signaling, and whether this affects its activity in diphthamide synthesis. This can be done by combining DPH6 antibody immunoprecipitation with phospho-specific detection methods.

• Real-time monitoring: Develop live-cell imaging approaches using fluorescently tagged DPH6 antibody fragments to track dynamic changes in DPH6 localization during cellular stress responses or pathway activation.

The research demonstrating that diphthamide-deficient cells are hypersensitive to TNF-mediated apoptosis suggests that DPH6 and the diphthamide pathway may serve as unexpected modulators of inflammatory responses , opening new avenues for investigation using these antibody-based approaches.

What techniques can be used to investigate the structural interactions between DPH6, eEF2, and other potential binding partners?

Advanced structural biology techniques can elucidate the detailed interactions between DPH6, eEF2, and other binding partners:

• Cryo-electron microscopy (cryo-EM): This technique has revolutionized structural biology and can be used to visualize the DPH6-eEF2 complex at near-atomic resolution. DPH6 antibodies can aid in complex stabilization or identification during sample preparation.

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS): This approach can map protein interaction interfaces between DPH6 and eEF2 by measuring changes in hydrogen/deuterium exchange rates upon complex formation, providing insights into binding dynamics.

• FRET-based interaction assays: Förster resonance energy transfer assays using fluorescently labeled antibody fragments can detect proximity between DPH6 and its binding partners in live cells, revealing temporal aspects of these interactions.

• Surface plasmon resonance (SPR): Quantitative binding kinetics between purified DPH6 and potential partners can be measured using SPR, with DPH6 antibodies potentially serving as capture reagents for oriented immobilization.

• Cross-linking mass spectrometry (XL-MS): Chemical cross-linking combined with mass spectrometry can map specific residues involved in the interaction between DPH6, eEF2, and other proteins in the diphthamide synthesis complex.

Studies have shown that DPH6 contains an essential adenine nucleotide hydrolase domain and directly binds to eEF2 . Further, research in yeast systems suggests that another protein, DPH7, may regulate the interaction between diphthamide pathway proteins and eEF2, indicating a complex network of interactions that merit detailed structural investigation .

What controls should be included when using DPH6 antibodies in immunoassays?

When designing immunoassays with DPH6 antibodies, the following controls are essential:

• Positive controls:

  • Wild-type cell lysates or tissues known to express DPH6

  • Recombinant DPH6 protein (if available)

  • Cell lines overexpressing tagged DPH6 (e.g., HA-tagged DPH6 as used in previous studies)

• Negative controls:

  • Lysates from DPH6 knockout cells (these should show diphthine accumulation in eEF2)

  • Pre-immune serum in place of primary antibody

  • Isotype control antibody from the same species as the DPH6 antibody

  • Blocking peptide competition (incubation with the antigen peptide should abolish specific signals)

• Cross-reactivity controls:

  • Testing against other DPH family proteins (especially DPH7, which functions in the same step)

  • Testing in species not targeted by the antibody

  • Samples expressing known DPH6 variants or isoforms

• Technical controls:

  • Loading controls (e.g., housekeeping proteins)

  • Omission of primary antibody

  • For conjugated antibodies, unconjugated isotype control

  • Gradient dilution series to establish linear range of detection

These controls help distinguish specific signals from non-specific background and validate antibody performance across applications .

What are the best methods for assessing diphthamide modification in cells treated with DPH6-targeting agents?

To evaluate diphthamide modification status in cells following DPH6 manipulation:

• ADP-ribosylation assays: The most established approach involves treating cell lysates with diphtheria toxin (DT) and monitoring ADP-ribosylation of eEF2. Cells lacking diphthamide modification (like DPH6 knockout cells) show resistance to DT-mediated ADP-ribosylation in vitro .

• Mass spectrometry analysis: High-resolution mass spectrometry can directly detect diphthine accumulation (the intermediate before diphthamide) in DPH6-deficient cells. This provides direct biochemical evidence of a block in the final amidation step .

• Sordarin sensitivity tests: Cells with defects in diphthamide synthesis show altered sensitivity to the antifungal agent sordarin, which can serve as a functional readout of diphthamide status .

• In vivo toxin expression assays: Expressing the ADP ribosylase domain of diphtheria toxin (DTA) within cells can distinguish between complete absence of diphthamide (strong resistance) and partial modification defects (intermediate resistance) .

• Ribosomal frameshifting assays: Since diphthamide modification affects translational accuracy, measuring -1 frameshifting rates using reporter constructs can indirectly assess diphthamide status .

The combination of these approaches provides complementary evidence for diphthamide modification status .

How should researchers interpret contradictory results between DPH6 antibody signals and functional diphthamide assays?

When faced with discrepancies between DPH6 antibody detection and functional diphthamide assays:

• Verify antibody specificity: Confirm that the DPH6 antibody is detecting the correct protein using knockout controls and western blotting. Non-specific binding can produce misleading signals that don't correlate with functional outcomes .

• Consider protein stability vs. activity: DPH6 may be present (detectable by antibody) but enzymatically inactive due to mutations or post-translational modifications. This distinction is important as research has shown that specific domains, such as the adenine nucleotide hydrolase domain, are essential for DPH6 function .

• Examine DPH7 status: Studies indicate that DPH7 couples diphthine synthase (DPH5) to diphthine amidation by DPH6. Dysfunction in DPH7 could affect DPH6 activity without altering DPH6 protein levels, creating a discrepancy between antibody detection and functional assays .

• Assess partial modification: Research has shown that in some cases, intermediate diphthamide pathway products (like diphthine) can serve as suboptimal substrates for processes that normally require complete diphthamide modification, but only under certain conditions (e.g., high concentrations of DT or overexpression of toxin components) . This can lead to seemingly contradictory results in different assay systems.

• Evaluate technical differences in assay sensitivity: For example, DPH6/7 mutants showed resistance to diphtheria toxin in vitro but only partial resistance when toxin was overexpressed in vivo , suggesting assay-dependent outcomes.

What are common technical challenges when working with DPH6 antibodies and how can they be overcome?

Researchers frequently encounter these technical challenges when working with DPH6 antibodies:

• Background signal in immunoblotting:

  • Challenge: High background can obscure specific DPH6 signals.

  • Solutions: Optimize blocking conditions (try different blockers like BSA, milk, or commercial alternatives); increase washing duration and detergent concentration; reduce primary antibody concentration; consider using more sensitive detection systems with lower antibody amounts.

• Variability in immunoprecipitation efficiency:

  • Challenge: Inconsistent pull-down of DPH6 or associated complexes.

  • Solutions: Pre-clear lysates thoroughly; validate antibody batch performance with positive controls; optimize lysis conditions to preserve protein-protein interactions; consider crosslinking approaches for transient interactions; use gentle elution methods to maintain complex integrity.

• Epitope masking in fixed tissues or cells:

  • Challenge: Fixation can mask epitopes recognized by DPH6 antibodies.

  • Solutions: Test different fixation methods; incorporate antigen retrieval steps; adjust antibody concentration; consider live-cell approaches for dynamic studies.

• Cross-reactivity with related proteins:

  • Challenge: Antibodies may detect other ATP-binding domain-containing proteins.

  • Solutions: Validate specificity using DPH6 knockout cells; perform peptide competition assays; use multiple antibodies recognizing different epitopes; confirm key findings with complementary non-antibody methods.

• Reconciling antibody-based and functional data:

  • Challenge: DPH6 detection may not correlate with diphthamide pathway functionality.

  • Solutions: Implement parallel functional assays examining diphthamide-dependent processes; combine antibody detection with eEF2 modification status analysis; include DPH7 assessment, as it regulates DPH6 function .

When designing experiments with DPH6 antibodies, researchers should plan for these challenges and include appropriate controls to distinguish specific signals from technical artifacts .

How might computational approaches enhance DPH6 antibody design and experimental planning?

Advanced computational methods offer promising opportunities for DPH6 antibody research:

• Machine learning for antibody design: Emerging approaches like the DyAb model demonstrate the potential for sequence-based antibody design even with limited training data. These methods could be applied to develop improved DPH6 antibodies with enhanced specificity and affinity, particularly important given the challenging nature of generating antibodies against components of the diphthamide synthesis pathway .

• Molecular dynamics simulations: Computational modeling of DPH6-antibody interactions can predict binding epitopes, optimize binding conditions, and enhance experimental design before wet-lab validation. These simulations can account for the adenine nucleotide hydrolase domain that is essential for DPH6 function .

• Network analysis of diphthamide pathway interactions: Computational analysis of protein-protein interaction networks can reveal unexpected connections between DPH6 and broader cellular processes, guiding antibody application in new research areas. This is particularly relevant given the discovery that diphthamide modification influences NF-κB and TNF receptor signaling pathways .

• Automated DOE optimization: Sophisticated DOE software can generate optimal experimental designs that maximize information while minimizing resource utilization, particularly valuable for complex multi-parameter studies involving DPH6 antibodies .

• Predictive modeling of diphthamide pathway defects: Machine learning approaches could potentially predict cellular consequences of DPH6 dysfunction based on patterns identified across multiple experimental systems, helping researchers prioritize the most promising research directions.

These computational approaches, when integrated with traditional experimental methods, can accelerate discovery and enhance research efficiency in studying this complex post-translational modification system .

What are promising applications of DPH6 antibodies in studying disease mechanisms related to translation dysregulation?

DPH6 antibodies offer unique opportunities for investigating disease mechanisms involving translation regulation:

• Cancer research applications: Studies with MCF7 breast cancer cells have already established that diphthamide-deficient cells show altered sensitivity to TNF-mediated apoptosis . DPH6 antibodies could help determine whether diphthamide status varies across cancer types and correlates with treatment response or disease progression.

• Neurodegenerative disease investigations: Given that translational fidelity is crucial for neuronal function, and diphthamide modification affects translational accuracy, DPH6 antibodies could help explore whether diphthamide pathway dysregulation contributes to neurodegenerative disorders characterized by protein misfolding.

• Infectious disease research: Since diphthamide modification is the target for bacterial toxins like diphtheria toxin and Pseudomonas exotoxin A , DPH6 antibodies could facilitate studies on host-pathogen interactions and potential therapeutic interventions that modulate diphthamide formation.

• Developmental biology applications: DPH6 antibodies could help track diphthamide synthesis during embryonic development and cell differentiation, potentially revealing stage-specific requirements for translational accuracy.

• Aging research: As translational fidelity generally declines with age, investigating whether diphthamide pathway components like DPH6 are affected during aging could provide insights into age-related pathologies.

These applications extend beyond the traditional use of DPH6 antibodies in basic research and highlight their potential value in understanding complex disease mechanisms related to translation dysregulation .

How can DPH6 antibody-based approaches be combined with CRISPR-Cas9 technology to advance diphthamide research?

Integrating DPH6 antibodies with CRISPR-Cas9 technology creates powerful research strategies:

• Genetic screening with immunological validation: CRISPR screens targeting diphthamide pathway regulators can be validated using DPH6 antibodies to confirm altered protein expression or localization in hits. This combination can identify novel factors influencing DPH6 function and diphthamide synthesis.

• Structure-function studies: CRISPR-mediated introduction of point mutations in DPH6, particularly in the adenine nucleotide hydrolase domain , followed by antibody-based detection and activity assays, can map critical functional regions of the protein with precision.

• Tagged endogenous protein analysis: CRISPR-mediated knock-in of epitope tags or fluorescent proteins at the DPH6 locus, combined with validated antibodies, enables tracking of endogenous protein dynamics without overexpression artifacts.

• Domain-specific functions: CRISPR can generate specific domain deletions in DPH6, with antibody detection confirming expression of truncated proteins, allowing dissection of domain-specific functions in diphthamide synthesis.

• Cell type-specific analysis: Combining tissue-specific CRISPR systems with immunohistochemistry using DPH6 antibodies can reveal cell type-specific requirements for diphthamide modification in complex tissues or organisms.

This integrated approach leverages the precision of CRISPR-Cas9 genetic manipulation with the detection capabilities of DPH6 antibodies to advance understanding of diphthamide biosynthesis mechanisms .

What mass spectrometry approaches are most effective when used in conjunction with DPH6 antibodies for studying diphthamide modification?

Optimized mass spectrometry (MS) strategies that complement DPH6 antibody applications include:

• Immunoprecipitation-mass spectrometry (IP-MS): Using DPH6 antibodies to pull down protein complexes followed by MS analysis can identify novel interaction partners and regulatory components of the diphthamide synthesis machinery. This approach is particularly valuable given the known interactions between DPH6, eEF2, and potentially DPH7 .

• Selected reaction monitoring (SRM)/multiple reaction monitoring (MRM): These targeted MS approaches can quantify specific diphthamide pathway components and modification states with high sensitivity. When combined with DPH6 antibody-based enrichment, they can detect low-abundance modified peptides from complex samples.

• Top-down proteomics: Analysis of intact eEF2 protein can distinguish between different modification states (unmodified, diphthine-modified, diphthamide-modified), providing direct evidence of DPH6 activity in various experimental conditions or disease states .

• Crosslinking mass spectrometry (XL-MS): Chemical crosslinking of protein complexes containing DPH6, followed by antibody-based enrichment and MS analysis, can map interaction interfaces and structural relationships between diphthamide pathway components.

• Parallel reaction monitoring (PRM): This targeted approach can quantify specific diphthamide-modified peptides with high precision, allowing comparison across different experimental conditions or in response to DPH6 manipulation.

When implementing these approaches, researchers should consider:

These mass spectrometry approaches, when combined with DPH6 antibody techniques, provide complementary data on diphthamide pathway regulation and function .

What validation steps are essential before using a new lot of DPH6 antibody in critical experiments?

Before employing a new lot of DPH6 antibody in key experiments, researchers should complete these validation steps:

• Western blot verification: Confirm that the antibody detects a band of the expected molecular weight (~63 kDa for human DPH6) in positive control samples but not in DPH6 knockout controls. Compare signal intensity and background with previously validated lots .

• Peptide competition assay: Pre-incubate the antibody with excess immunizing peptide to verify that specific signals are abolished, confirming epitope specificity.

• Cross-reactivity assessment: Test the antibody on samples containing related proteins (especially other diphthamide synthesis components) to ensure specificity for DPH6 over similar proteins.

• Application-specific validation: For each intended application (ELISA, immunoprecipitation, immunofluorescence), verify performance using established positive controls under standard conditions.

• Functional correlation: Confirm that antibody detection correlates with functional readouts of diphthamide pathway activity, such as ADP-ribosylation assays or diphthine accumulation .

• Titration experiments: Determine optimal working concentrations for each application by testing dilution series, establishing the minimum antibody concentration that yields reliable signals.

• Reproducibility testing: Perform replicate experiments to ensure consistent results across multiple samples and experimental conditions.

Thorough validation saves resources by preventing failed experiments and ensures reliable, interpretable results in subsequent research applications .

How should researchers integrate findings from DPH6 antibody studies with broader translation regulation research?

To effectively integrate DPH6 antibody-based findings with the broader field of translation regulation:

• Connect diphthamide modification to specific translation outcomes: Use DPH6 antibodies to correlate diphthamide status with measurable translation metrics such as frameshifting rates, translational accuracy, and ribosome stalling at specific codons. Research has already established links between diphthamide modification and translational fidelity .

• Examine tissue-specific and developmental contexts: Apply DPH6 antibodies to investigate whether diphthamide synthesis varies across tissues or developmental stages, potentially revealing context-specific requirements for this modification in translation regulation.

• Explore stress response connections: Determine whether cellular stresses alter DPH6 levels or activity using antibody-based detection, potentially uncovering a role for diphthamide modification in stress-responsive translation regulation.

• Integrate with ribosome profiling data: Combine DPH6 antibody studies with ribosome profiling to identify specific mRNAs or translation contexts most affected by diphthamide status, revealing pathway-specific translation regulation.

• Consider species-specific differences: Use cross-reactive DPH6 antibodies to compare diphthamide pathway conservation across evolutionary lineages, contextualizing findings within broader translation mechanism evolution.

• Link to disease-relevant translation dysregulation: Apply DPH6 antibodies in disease models characterized by translation defects to determine whether diphthamide pathway components represent potential therapeutic targets. The connection to NF-κB and TNF receptor pathways already suggests broader implications beyond translation .